Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy

被引:159
作者
Ortiz, Alberto [1 ]
Oliveira, Joao P. [2 ]
Waldek, Steven [3 ]
Warnock, David G. [4 ]
Cianciaruso, Bruno [5 ]
Wanner, Christoph [6 ]
机构
[1] Fdn Jimenez Diaz, Unidad Dialisis, E-28040 Madrid, Spain
[2] Hosp Sao Joao, Oporto, Portugal
[3] Hope Hosp, Salford M6 8HD, Lancs, England
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Univ Naples Federico II, Div Nephrol, Naples, Italy
[6] Univ Wurzburg, Univ Hosp, Div Nephrol, Wurzburg, Germany
关键词
blood pressure; Fabry disease; nephropathy; proteinuria; registry;
D O I
10.1093/ndt/gfm848
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Fabry disease, an X-linked genetic disorder with deficient alpha-galactosidase A activity, is characterized by kidney disease and kidney failure. The spectrum of kidney disease has not been well defined, especially in female patients. Methods. We did a cross-sectional retrospective analysis of natural history of glomerular filtration rate(estimated-eGFR), albuminuria and proteinuria in 1262 adult patients (585 males, 677 females) from the Fabry Registry. Results. Twenty-eight percent of males (age 20-79 years) and 13% of females (age 20-82 years) had chronic kidney disease (CKD) with eGFR < 60 ml/min/1.73 m(2). Overt proteinuria (> 300 mg/24 h) was demonstrated in 43 and 26% of males and females with CKD stage 1, respectively, and the proportions were higher with more severe kidney involvement. However, 11% of males and 28% of females with eGFR < 60 ml/min/1.73 m(2) had proteinuria < 300 mg/ 24 h. Of eGFR >= 60 ml/min/1.73 m(2) patients without overt proteinuria (n = 93), 55% of the males and 35% of the females had albuminuria > 30 mg/24 h. Systemic blood pressure was >= 130/80 mmHg in 48% and 67% of patients with eGFR >= and < 60 ml/min/1.73 m(2), respectively, with no significant differences between males and females. Proteinuria values were significantly correlated with systolic blood pressure in both sexes. Conclusions. Kidney involvement in Fabry disease is more prevalent and heterogeneous than previously reported. Proteinuria is an early complication, but may not be overt in patients with advanced kidney disease. This analysis, which includes more females than males, confirms that a significant proportion of females suffer moderate to severe kidney involvement in Fabry disease.
引用
收藏
页码:1600 / 1607
页数:8
相关论文
共 36 条
[1]   RENAL ABNORMALITIES IN SICKLE-CELL DISEASE [J].
ALLON, M .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (03) :501-504
[2]   Agalsidase-beta therapy for advanced Fabry disease - A randomized trial [J].
Banikazemi, Maryam ;
Bultas, Jan ;
Waldek, Stephen ;
Wilcox, William R. ;
Whitley, Chester B. ;
McDonald, Marie ;
Finkel, Richard ;
Packman, Seymour ;
Bichet, Daniel G. ;
Warnock, David G. ;
Desnick, Robert J. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) :77-86
[3]   DIABETES-LIKE RENAL GLOMERULAR-DISEASE IN FANCONI-BICKEL SYNDROME [J].
BERRY, GT ;
BAKER, L ;
KAPLAN, FS ;
WITZLEBEN, CL .
PEDIATRIC NEPHROLOGY, 1995, 9 (03) :287-291
[4]   Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course [J].
Branton, MH ;
Schiffmann, R ;
Sabnis, SG ;
Murray, GJ ;
Quirk, JM ;
Altarescu, G ;
Goldfarb, L ;
Brady, RO ;
Balow, JE ;
Austin, HA ;
Kopp, JB .
MEDICINE, 2002, 81 (02) :122-138
[5]   Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort [J].
Buckalew, VM ;
Berg, RL ;
Wang, SR ;
Porush, JG ;
Rauch, S ;
Schulman, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (06) :811-821
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[7]   Natural history of Fabry disease in females in the Fabry outcome survey [J].
Deegan, PB ;
Baehner, AF ;
Romero, MAB ;
Hughes, DA ;
Kampmann, C ;
Beck, M .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (04) :347-352
[8]   ANGIOKERATOMA CORPORIS DIFFUSUM FABRY [J].
DEGROOT, WP .
DERMATOLOGICA, 1968, 136 (05) :432-&
[9]  
Desnick R.J., 2001, The Metabolic Molecular Bases of Inherited Disease ed. by, V16, P3733, DOI [10.1036/ommbid.181, DOI 10.1036/OMMBID.181]
[10]   Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. [J].
Eng, CM ;
Guffon, N ;
Wilcox, WR ;
Germain, DP ;
Lee, P ;
Waldek, S ;
Caplan, L ;
Linthorst, GE ;
Desnick, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :9-16